Last reviewed · How we verify
NCT05402592
The Effect of Oral Carbohydrate Administration on Postoperative Well-being
NA trial testing Carbonhydrate rich drink in Colorectal Cancer in 50 participants. Completed in 1 April 2023.
1 December 2022
Quick facts
| Lead sponsor | Muğla Sıtkı Koçman University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 50 |
| Start date | 13 July 2022 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 April 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Carbonhydrate rich drink
- Water (WATER) — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Glucometabolic Response — all drugs for Glucometabolic Response →
- Subjective Goodness — all drugs for Subjective Goodness →
- Life Quality — all drugs for Life Quality →
Sponsor
Muğla Sıtkı Koçman University
Who can join
18 and older, any sex, with Colorectal Cancer or Glucometabolic Response. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Studies have shown that clear liquids containing carbohydrates are safe when given up to 2 hours before surgery and increase patient comfort before surgery. In the light of this information, this study aims to investigate the effects of preoperative oral carbohydrate administration on postoperative glucometabolic response, subjective well-being, quality of life, and surgical clinical outcomes in patients scheduled for colorectal surgery; planned as randomized-controlled, double-blind
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The effect of preoperative oral carbohydrate administration on postoperative glucometabolic response, subjective well being and quality of life in patients undergoing colorectal surgery: a randomized controlled double-blind study.
Urkan M, Celebi C, Meral UM, Cavdar I. · · 2025 · cited 2× · PMID 40830867 · DOI 10.1186/s12893-025-03093-3
Verify or expand the search:
- PubMed search for NCT05402592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Muğla Sıtkı Koçman University trials
Trials by the same sponsor.
- NCT05046834 — Effect of Cold Application on Patient's Pain and Vital Signs During Chest Tube Removal. · NA · withdrawn
- NCT07323160 — Determining the Effect of Education Given to Patients Undergoing Outpatient Anal Fistula Surgery · NA · not yet recruiting
- NCT07308730 — Pain Diary Use After Laparoscopic Cholecystectomy · NA · recruiting
- NCT06704399 — Psychoeducation Based on Acceptance and Commitment Therapy · NA · not yet recruiting
- NCT07183956 — Comparison of the Silverman-Andersen Score and the Downes Score · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05402592 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Muğla Sıtkı Koçman University
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05402592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing